BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

393 related articles for article (PubMed ID: 33401953)

  • 1. Statin Exposure and Risk of Heart Failure After Anthracycline- or Trastuzumab-Based Chemotherapy for Early Breast Cancer: A Propensity Score‒Matched Cohort Study.
    Abdel-Qadir H; Bobrowski D; Zhou L; Austin PC; Calvillo-Argüelles O; Amir E; Lee DS; Thavendiranathan P
    J Am Heart Assoc; 2021 Jan; 10(2):e018393. PubMed ID: 33401953
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characteristics and Outcomes of Women Developing Heart Failure After Early Stage Breast Cancer Chemotherapy: A Population-Based Matched Cohort Study.
    Abdel-Qadir H; Tai F; Croxford R; Austin PC; Amir E; Calvillo-Argüelles O; Ross H; Lee DS; Thavendiranathan P
    Circ Heart Fail; 2021 Jul; 14(7):e008110. PubMed ID: 34187164
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of statin therapy on the risk for incident heart failure in patients with breast cancer receiving anthracycline chemotherapy: an observational clinical cohort study.
    Seicean S; Seicean A; Plana JC; Budd GT; Marwick TH
    J Am Coll Cardiol; 2012 Dec; 60(23):2384-90. PubMed ID: 23141499
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risk of heart failure in breast cancer patients after anthracycline and trastuzumab treatment: a retrospective cohort study.
    Bowles EJ; Wellman R; Feigelson HS; Onitilo AA; Freedman AN; Delate T; Allen LA; Nekhlyudov L; Goddard KA; Davis RL; Habel LA; Yood MU; McCarty C; Magid DJ; Wagner EH;
    J Natl Cancer Inst; 2012 Sep; 104(17):1293-305. PubMed ID: 22949432
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Breast Cancer Therapy-Related Cardiac Dysfunction in Adult Women Treated in Routine Clinical Practice: A Population-Based Cohort Study.
    Thavendiranathan P; Abdel-Qadir H; Fischer HD; Camacho X; Amir E; Austin PC; Lee DS
    J Clin Oncol; 2016 Jul; 34(19):2239-46. PubMed ID: 27091709
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cardioprotective Effect of Statins in Patients With HER2-Positive Breast Cancer Receiving Trastuzumab Therapy.
    Calvillo-Argüelles O; Abdel-Qadir H; Michalowska M; Billia F; Suntheralingam S; Amir E; Thavendiranathan P
    Can J Cardiol; 2019 Feb; 35(2):153-159. PubMed ID: 30760421
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cardiotoxicity and Cardiac Monitoring Among Chemotherapy-Treated Breast Cancer Patients.
    Henry ML; Niu J; Zhang N; Giordano SH; Chavez-MacGregor M
    JACC Cardiovasc Imaging; 2018 Aug; 11(8):1084-1093. PubMed ID: 30092967
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cardiac safety of non-anthracycline trastuzumab-based therapy for HER2-positive breast cancer.
    Yu AF; Mukku RB; Verma S; Liu JE; Oeffinger KC; Steingart RM; Hudis CA; Dang CT
    Breast Cancer Res Treat; 2017 Nov; 166(1):241-247. PubMed ID: 28710537
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Statins to mitigate cardiotoxicity in cancer patients treated with anthracyclines and/or trastuzumab: a systematic review and meta-analysis.
    Obasi M; Abovich A; Vo JB; Gao Y; Papatheodorou SI; Nohria A; Asnani A; Partridge AH
    Cancer Causes Control; 2021 Dec; 32(12):1395-1405. PubMed ID: 34406595
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prevention of Trastuzumab and Anthracycline-induced Cardiotoxicity Using Angiotensin-converting Enzyme Inhibitors or β-blockers in Older Adults With Breast Cancer.
    Wittayanukorn S; Qian J; Westrick SC; Billor N; Johnson B; Hansen RA
    Am J Clin Oncol; 2018 Sep; 41(9):909-918. PubMed ID: 28537988
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Temporal Risk of Heart Failure Associated With Adjuvant Trastuzumab in Breast Cancer Patients: A Population Study.
    Goldhar HA; Yan AT; Ko DT; Earle CC; Tomlinson GA; Trudeau ME; Krahn MD; Krzyzanowska MK; Pal RS; Brezden-Masley C; Gavura S; Lien K; Chan KK
    J Natl Cancer Inst; 2016 Jan; 108(1):. PubMed ID: 26476433
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risk of heart failure after systemic treatment for early breast cancer: results of a cohort study.
    Jacobse JN; Schaapveld M; Boekel NB; Hooning MJ; Jager A; Baaijens MHA; Hauptmann M; Russell NS; Rutgers EJT; Aleman BMP; Sonke GS; van Leeuwen FE
    Breast Cancer Res Treat; 2021 Jan; 185(1):205-214. PubMed ID: 32964358
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Statins as preventive therapy for anthracycline cardiotoxicity: a meta-analysis of randomized controlled trials.
    D'Amario D; Laborante R; Bianchini E; Galli M; Ciliberti G; Mennuni M; Patti G
    Int J Cardiol; 2023 Nov; 391():131219. PubMed ID: 37527752
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Heart failure after treatment for breast cancer.
    Boekel NB; Duane FK; Jacobse JN; Hauptmann M; Schaapveld M; Sonke GS; Gietema JA; Hooning MJ; Seynaeve CM; Maas AHEM; Darby SC; Aleman BMP; Taylor CW; van Leeuwen FE
    Eur J Heart Fail; 2020 Feb; 22(2):366-374. PubMed ID: 31721395
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Risk of Heart Failure and Other Cardiovascular Hospitalizations After Early Stage Breast Cancer: A Matched Cohort Study.
    Abdel-Qadir H; Thavendiranathan P; Austin PC; Lee DS; Amir E; Tu JV; Fung K; Anderson GM
    J Natl Cancer Inst; 2019 Aug; 111(8):854-862. PubMed ID: 30715404
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cardioprotective effect of β-adrenoceptor blockade in patients with breast cancer undergoing chemotherapy: follow-up study of heart failure.
    Seicean S; Seicean A; Alan N; Plana JC; Budd GT; Marwick TH
    Circ Heart Fail; 2013 May; 6(3):420-6. PubMed ID: 23425978
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Trastuzumab-induced cardiotoxicity in elderly women with HER-2-positive breast cancer: a meta-analysis of real-world data.
    Leung HW; Chan AL
    Expert Opin Drug Saf; 2015; 14(11):1661-71. PubMed ID: 26461271
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Decline in Left Ventricular Ejection Fraction Following Anthracyclines Predicts Trastuzumab Cardiotoxicity.
    Goel S; Liu J; Guo H; Barry W; Bell R; Murray B; Lynch J; Bastick P; Chantrill L; Kiely BE; Abdi E; Rutovitz J; Asghari R; Sullivan A; Harrison M; Kohonen-Corish M; Beith J
    JACC Heart Fail; 2019 Sep; 7(9):795-804. PubMed ID: 31401102
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Trastuzumab and target-therapy side effects: Is still valid to differentiate anthracycline Type I from Type II cardiomyopathies?
    Riccio G; Coppola C; Piscopo G; Capasso I; Maurea C; Esposito E; De Lorenzo C; Maurea N
    Hum Vaccin Immunother; 2016 May; 12(5):1124-31. PubMed ID: 26836985
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Global Longitudinal Strain Accuracy for Cardiotoxicity Prediction in a Cohort of Breast Cancer Patients During Anthracycline and/or Trastuzumab Treatment.
    Gripp EA; Oliveira GE; Feijó LA; Garcia MI; Xavier SS; Sousa AS
    Arq Bras Cardiol; 2018 Feb; 110(2):140-150. PubMed ID: 29561992
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.